No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ALVOAlvotech | 1.54B | 4.95 | -5.69 | 435.56% | 12.17% |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 66.62M | 36.77M | 83.03M | 91.43M | 489.68M |
| Revenue Growth % | - | -0.45% | 1.26% | 0.1% | 4.36% |
| Cost of Goods Sold | 0 | 0 | 64.09M | 160.86M | 185.31M |
| COGS % of Revenue | - | - | 0.77% | 1.76% | 0.38% |
| Gross Profit | 66.62M | 36.77M | 18.93M | -69.42M | 304.37M |
| Gross Margin % | 1% | 1% | 0.23% | -0.76% | 0.62% |
| Gross Profit Growth % | - | -0.45% | -0.49% | -4.67% | 5.38% |
| Operating Expenses | 204.15M | 272.23M | 365.38M | 285.44M | 234.73M |
| OpEx % of Revenue | 3.06% | 7.4% | 4.4% | 3.12% | 0.48% |
| Selling, General & Admin | 58.91M | 84.13M | 186.74M | 73.04M | 61.45M |
| SG&A % of Revenue | 0.88% | 2.29% | 2.25% | 0.8% | 0.13% |
| Research & Development | 148.07M | 191.01M | 180.62M | 210.83M | 171.31M |
| R&D % of Revenue | 2.22% | 5.19% | 2.18% | 2.31% | 0.35% |
| Other Operating Expenses | -2.83M | -2.91M | -1.99M | 1.57M | 1.96M |
| Operating Income | -137.54M | -235.46M | -346.44M | -354.86M | 69.64M |
| Operating Margin % | -2.06% | -6.4% | -4.17% | -3.88% | 0.14% |
| Operating Income Growth % | - | -0.71% | -0.47% | -0.02% | 1.2% |
| EBITDA | -121.12M | -217.26M | -326.03M | -330.65M | 100.94M |
| EBITDA Margin % | -1.82% | -5.91% | -3.93% | -3.62% | 0.21% |
| EBITDA Growth % | - | -0.79% | -0.5% | -0.01% | 1.31% |
| D&A (Non-Cash Add-back) | 16.42M | 18.2M | 20.41M | 24.21M | 31.3M |
| EBIT | -194.3M | -36.23M | -460.21M | -517.88M | -63.58M |
| Net Interest Income | -433.19K | -112.95M | -90.53M | -130M | -152.98M |
| Interest Income | - | 19K | 912K | 4.82M | 4.62M |
| Interest Expense | 433.19K | 112.97M | 91.44M | 134.82M | 157.6M |
| Other Income/Expense | -154.23M | 86.26M | -205.21M | -296.19M | -287.21M |
| Pretax Income | -291.77M | -149.2M | -551.65M | -651.05M | -217.56M |
| Pretax Margin % | -4.38% | -4.06% | -6.64% | -7.12% | -0.44% |
| Income Tax | -121.73M | -47.69M | -38.07M | -99.32M | 14.3M |
| Effective Tax Rate % | 0.58% | 0.68% | 0.93% | 0.85% | 1.07% |
| Net Income | -170.04M | -101.5M | -513.58M | -551.73M | -231.86M |
| Net Margin % | -2.55% | -2.76% | -6.19% | -6.03% | -0.47% |
| Net Income Growth % | - | 0.4% | -4.06% | -0.07% | 0.58% |
| Net Income (Continuing) | -170.04M | -101.5M | -513.58M | -551.73M | -231.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.44 | -3.25 | -2.60 | -2.43 | -0.87 |
| EPS Growth % | - | 0.4% | 0.2% | 0.07% | 0.64% |
| EPS (Basic) | -5.44 | -3.25 | -2.60 | -2.43 | -0.87 |
| Diluted Shares Outstanding | 31.25M | 31.25M | 197.72M | 227.26M | 267.92M |
| Basic Shares Outstanding | 31.25M | 31.25M | 197.72M | 227.26M | 267.92M |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 86.16M | 119.82M | 230.74M | 194.84M | 455.02M |
| Cash & Short-Term Investments | 31.69M | 17.56M | 66.43M | 11.16M | 51.43M |
| Cash Only | 31.69M | 17.56M | 66.43M | 11.16M | 51.43M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 33.12M | 53.88M | 71.39M | 87.22M | 251.72M |
| Days Sales Outstanding | 181.45 | 534.83 | 313.82 | 348.17 | 187.63 |
| Inventory | 9.65M | 39.06M | 71.47M | 74.43M | 127.89M |
| Days Inventory Outstanding | - | - | 407 | 168.9 | 251.9 |
| Other Current Assets | 5.79M | 0 | 851K | 0 | 0 |
| Total Non-Current Assets | 388.26M | 478.16M | 597.71M | 755.25M | 766.38M |
| Property, Plant & Equipment | 176.97M | 205.33M | 268.1M | 356.58M | 409.74M |
| Fixed Asset Turnover | 0.38x | 0.18x | 0.31x | 0.26x | 1.20x |
| Goodwill | 13.43M | 12.37M | 11.64M | 12.06M | 11.33M |
| Intangible Assets | 6.33M | 21.51M | 25.65M | 19.08M | 20.62M |
| Long-Term Investments | 56.68M | 55.31M | 48.57M | 18.49M | 22.71M |
| Other Non-Current Assets | 134.85M | 13.23M | 34.25M | 39.23M | 3.62M |
| Total Assets | 474.42M | 597.98M | 828.44M | 950.09M | 1.22B |
| Asset Turnover | 0.14x | 0.06x | 0.10x | 0.10x | 0.40x |
| Asset Growth % | - | 0.26% | 0.39% | 0.15% | 0.29% |
| Total Current Liabilities | 50.98M | 111.84M | 167.29M | 260.95M | 193.4M |
| Accounts Payable | 11.96M | 28.59M | 49.19M | 80.56M | 67.13M |
| Days Payables Outstanding | - | - | 280.11 | 182.81 | 132.22 |
| Short-Term Debt | 2.5M | 2.77M | 19.92M | 38.02M | 32.7M |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 14.63M | 0 | 0 | 34.5M | 6.63M |
| Current Ratio | 1.69x | 1.07x | 1.38x | 0.75x | 2.35x |
| Quick Ratio | 1.50x | 0.72x | 0.95x | 0.46x | 1.69x |
| Cash Conversion Cycle | - | - | 440.71 | 334.26 | 307.31 |
| Total Non-Current Liabilities | 1.29B | 621.75M | 1.23B | 1.62B | 1.44B |
| Long-Term Debt | 565.4M | 398.14M | 744.65M | 922.13M | 1.04B |
| Capital Lease Obligations | 103.47M | 114.84M | 35.37M | 105.63M | 112.14M |
| Deferred Tax Liabilities | 0 | 150K | 309K | 53K | 1.81M |
| Other Non-Current Liabilities | 621.82M | 63.77M | 388.22M | 520.55M | 210.22M |
| Total Liabilities | 1.34B | 733.59M | 1.39B | 1.88B | 1.63B |
| Total Debt | 676.85M | 523.05M | 805.1M | 1.08B | 1.19B |
| Net Debt | 645.16M | 505.5M | 738.67M | 1.06B | 1.14B |
| Debt / Equity | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | 11.79x |
| Net Debt / EBITDA | - | - | - | - | 11.28x |
| Interest Coverage | -317.50x | -2.08x | -3.79x | -2.63x | 0.44x |
| Total Equity | -867.24M | -135.61M | -564.42M | -932.49M | -412.77M |
| Equity Growth % | - | 0.84% | -3.16% | -0.65% | 0.56% |
| Book Value per Share | -27.75 | -4.34 | -2.85 | -4.10 | -1.54 |
| Total Shareholders' Equity | -867.24M | -135.61M | -564.42M | -932.49M | -412.77M |
| Common Stock | 73K | 135K | 2.13M | 2.28M | 2.83M |
| Retained Earnings | -1.04B | -1.14B | -1.65B | -2.21B | -2.44B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.97M | 4.67M | 29.14M | 41.38M | 15.05M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -74.3M | -228.17M | -312.39M | -312.19M | -236.84M |
| Operating CF Margin % | -1.12% | -6.2% | -3.76% | -3.41% | -0.48% |
| Operating CF Growth % | - | -2.07% | -0.37% | 0% | 0.24% |
| Net Income | -170.04M | -101.5M | -513.58M | -551.73M | -231.86M |
| Depreciation & Amortization | 16.42M | 18.2M | 20.41M | 24.21M | 31.3M |
| Stock-Based Compensation | 0 | 0 | 10.32M | 18.03M | 7.63M |
| Deferred Taxes | -121.73M | -47.69M | -38.07M | -99.32M | 14.3M |
| Other Non-Cash Items | 168.54M | -90.36M | 256.42M | 270.29M | 230.44M |
| Working Capital Changes | 32.52M | -6.81M | -47.89M | 26.33M | -288.64M |
| Change in Receivables | 10.1M | -13.53M | -13.23M | -24.83M | -164.24M |
| Change in Inventory | -3.25M | -29.41M | -32.41M | -11.3M | -49.97M |
| Change in Payables | 227K | 14.32M | 0 | 0 | 0 |
| Cash from Investing | -16.9M | -40.63M | -63.54M | -46.34M | -18.87M |
| Capital Expenditures | -7.49M | -20.46M | -37.88M | -33.23M | -53.66M |
| CapEx % of Revenue | 0.11% | 0.56% | 0.46% | 0.36% | 0.11% |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | -4.42M | -20.17M | -25.66M | -13.11M | 22.79M |
| Cash from Financing | 55.4M | 254.83M | 424.91M | 301.32M | 297.31M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | 0 | 0 | 157.27M | -6.75M | -5.13M |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | -86.28M | -268.8M | -361.39M | -358.66M | -293.84M |
| FCF Margin % | -1.3% | -7.31% | -4.35% | -3.92% | -0.6% |
| FCF Growth % | - | -2.12% | -0.34% | 0.01% | 0.18% |
| FCF per Share | -2.76 | -8.60 | -1.83 | -1.58 | -1.10 |
| FCF Conversion (FCF/Net Income) | 0.44x | 2.25x | 0.61x | 0.57x | 1.02x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Invested Capital (ROIC) | - | -238.97% | -95.5% | -173.9% | 12.18% |
| Gross Margin | 100% | 100% | 22.8% | -75.93% | 62.16% |
| Net Margin | -255.26% | -276.04% | -618.56% | -603.42% | -47.35% |
| Interest Coverage | -317.50x | -2.08x | -3.79x | -2.63x | 0.44x |
| FCF Conversion | 0.44x | 2.25x | 0.61x | 0.57x | 1.02x |
| Revenue Growth | - | -44.8% | 125.79% | 10.12% | 435.56% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Humira | - | 12.2B | - |
| Humira Growth | - | - | - |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| UNITED STATES | - | - | 273.04M |
| UNITED STATES Growth | - | - | - |
| Europe | 39.43M | 63.51M | 157.59M |
| Europe Growth | - | 61.06% | 148.13% |
| Rest Of The World | - | - | 59.06M |
| Rest Of The World Growth | - | - | - |
| North America | 30.78M | 18.31M | - |
| North America Growth | - | -40.53% | - |
| Asia And Other | - | 9.62M | - |
| Asia And Other Growth | - | - | - |
| Asia | 6.8M | - | - |
| Asia Growth | - | - | - |
| Other Geographical Area | 6.02M | - | - |
| Other Geographical Area Growth | - | - | - |
Alvotech (ALVO) reported $571.2M in revenue for fiscal year 2024. This represents a 757% increase from $66.6M in 2020.
Alvotech (ALVO) grew revenue by 435.6% over the past year. This is strong growth.
Yes, Alvotech (ALVO) is profitable, generating $69.5M in net income for fiscal year 2024 (-47.3% net margin).
Alvotech (ALVO) had negative free cash flow of $113.5M in fiscal year 2024, likely due to heavy capital investments.